Over the past five years, the South Korean pharmaceutical and biotech sector has emerged as a hotbed for Licensing and Mergers and Acquisitions (M&A) activity, attracting interest from both domestic and international players. Its unprecedented growth is fuelled by a combination of innovation, government support, and market expansion strategies, alongside the strategic need to access advanced technologies and global markets. This white paper provides an in-depth analysis of the key trends, drivers, and notable transactions that have shaped this dynamic sector, and highlights how international companies can benefit from this thriving market.

The European specialty pharma M&A landscape is undergoing significant transformations, with private equity firms facing new and unprecedented challenges. This white paper examines the current state of private equity within the sector, identifying the key obstacles and trends reshaping investment strategies.